Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

What Keeps Cancer Drug Developers Awake at Night

This article was originally published in Start Up

Executive Summary

The range of comments, as well as the general tone, of a recent clinical cancer meeting prompted us to ask developers of cancer drugs what they saw as the major issues and hurdles in designing and testing new compounds. Their comments suggest that empirical methodologies, albeit informed by understanding of the biology around a target, will dominate clinical thinking in the near term. Clinical setbacks over the past several years, a lack of validated biomarkers, and an awareness that preclinical models are of limited utility in establishing dose and identifying likely responders, have reinforced that perception. Developers' principal concerns therefore often focus on things that are within their control; in particular, how to resource and manage a program for the long haul.
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090837

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel